久久久久久久久久久96,爱草草在线观看免费视频,蜜臀精品人妻一区二区色戒

您好，歡迎來到拜力生物網(wǎng)站！請(qǐng)登錄注冊(cè)

我的訂單 | 聯(lián)系我們 | 在線客服QQ：3012681483 | 客服電話：400-968-7988 | 工作時(shí)間：08:30-17:30

主營產(chǎn)品： ELISA試劑盒、抗體、補(bǔ)體血清、兔補(bǔ)體、干擾素、小鼠測(cè)溫儀、進(jìn)口試劑、Quidel代理、Swant代理、PBL Assay Science代理

網(wǎng)站首頁產(chǎn)品中心代理品牌新聞資訊資源中心關(guān)于我們

所在位置：首頁 > 產(chǎn)品中心 > Xcessbio > Xcessbio產(chǎn)品

訂購信息

上海拜力生物科技公司

Tel:400-968-7988 021-33779008

SR1664,PPAR-γModulator

品牌：Xcessbio

貨號(hào)：M66048-2s

規(guī)格：2 mg solid

貨期：

應(yīng)用：

咨詢客服

立即購買加入購物車

SR1664,PPAR-γModulator

商品詳情參考文獻(xiàn) 相關(guān)資料

Product Information

Molecular Weight:	547.60
Formula:	C₃₃H₂₉N₃O₅
Purity:	≥98%
CAS#:	1338259-05-4
Solubility:	DMSO up to 25 mM
Chemical Name:	(S)-4'-((2,3-dimethyl-5-((1-(4-nitrophenyl)ethyl)carbamoyl)-1H-indol-1-yl)methyl)-[1,1'-biphenyl]-2-carboxylic acid
Storage:	Powder: 4^oC 1 year. DMSO: 4^oC 3 month; -20^oC 1 year.

Biological Activity:
SR1664 is a unique PPARγ modulator that has potent anti-diabetic activity. SR1664 has a unique tight binding mode to PPARγ (EC₅₀ ~80 nM), completely lacking classical transcriptional agonism and blocking the Cdk5-mediated phosphorylation of PPARγ (EC₅₀ ~200 nM) in cultured adipocytes and in insulin-resistant mice. It has potent antidiabetic activity while not causing the fluid retention and weight gain that are serious side effects of many PPARγ drugs. Unlike TZDs, SR1664 also does not interfere with bone formation in culture. It could be developed as new classes of antidiabetes drug specifically targeting the Cdk5-mediated phosphorylation of PPARγ.

How to Use:

In vitro: SR1664 was used at 2-10 μM final concentration in the in vitro assays.
In vivo: SR1664 was injected intraperitoneally at 40 mg/kg twice per day for 5 days and showed good efficacy in high-fat diet (HFD) and db/db mouse models.

Reference:

1. Choi JH, et al. Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation. (2011) Nature. 477(7365):477-81.
2. Norris AW, at al. A second chance for a PPARγ targeted therapy? (2012) Circ Res. 110(1):8-11.